Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Allogene Therapeutics Inc’s stock clocked out at $1.11, down -5.93% from its previous closing price of $1.18. In other words, the price has decreased by -$5.93 from its previous closing price. On the day, 2.1 million shares were traded. ALLO stock price reached its highest trading level at $1.17 during the session, while it also had its lowest trading level at $1.05.
Ratios:
To gain a deeper understanding of ALLO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.92 and its Current Ratio is at 8.92. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.23.
Citizens JMP Upgraded its Mkt Perform to Mkt Outperform on March 14, 2025, while the target price for the stock was maintained at $5.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 21 ’25 when Parker Geoffrey M. sold 36,744 shares for $1.26 per share. The transaction valued at 46,169 led to the insider holds 1,276,796 shares of the business.
Parker Geoffrey M. bought 36,744 shares of ALLO for $46,169 on Oct 21 ’25. On Jun 10 ’25, another insider, MESSEMER DEBORAH M., who serves as the Director of the company, sold 36,885 shares for $1.42 each. As a result, the insider received 52,377 and left with 107,431 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALLO now has a Market Capitalization of 246287936 and an Enterprise Value of 60164944.
Stock Price History:
The Beta on a monthly basis for ALLO is 0.49, which has changed by -0.6335404 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, ALLO has reached a high of $3.78, while it has fallen to a 52-week low of $0.86. The 50-Day Moving Average of the stock is -8.82%, while the 200-Day Moving Average is calculated to be -20.94%.
Shares Statistics:
It appears that ALLO traded 3.46M shares on average per day over the past three months and 2234970 shares per day over the past ten days. A total of 220.13M shares are outstanding, with a floating share count of 153.74M. Insiders hold about 30.71% of the company’s shares, while institutions hold 60.77% stake in the company. Shares short for ALLO as of 1760486400 were 19491965 with a Short Ratio of 5.64, compared to 1757894400 on 20285441. Therefore, it implies a Short% of Shares Outstanding of 19491965 and a Short% of Float of 10.6000006.
Earnings Estimates
Allogene Therapeutics Inc (ALLO) is currently under the scrutiny of 7.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.19 and low estimates of -$0.24.
Analysts are recommending an EPS of between -$0.96 and -$1.2 for the fiscal current year, implying an average EPS of -$1.03. EPS for the following year is -$0.98, with 10.0 analysts recommending between -$0.5 and -$1.47.
